Gastric lesions in 76 patients with adult T-cell leukemia/lymphoma. Endoscopic evaluation. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Gastric lesions in 76 patients with adult T-cell leukemia/lymphoma. Endoscopic evaluation.

Cancer. 1996 Aug 1;78(3):396-402. Unique Identifier : AIDSLINE MED/96320566
Sakata H; Fujimoto K; Iwakiri R; Mizuguchi M; Koyama T; Sakai T; Inoue E; Tokunaga O; Shimamoto Y; Division of Gastroenterology, Department of Internal Medicine,; Saga Medical School, Saga, Japan.


Abstract: BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is caused by human T-lymphotropic virus type I. Gastric lesions in ATLL have not been described precisely, whereas the clinical features of ATLL have been well documented. The goal of the present study was to review gastric lesions, including gastric involvement, of patients with ATLL who were admitted to our hospital. METHODS: Endoscopic examination of the upper gastrointestinal tract was performed on 76 of 110 patients who were admitted to our hospital between 1981 and 1994. Gastric involvement was diagnosed by histologic examination of biopsy specimens of gastric lesions. Types of gastric lesions, histologic features, and survival periods in patients with ATLL were summarized. RESULTS: Of the 76 patients with ATLL who underwent an endoscopic examination, 23 had gastric involvement (30.3%). Twenty-seven patients had other gastric lesions: 10 with peptic ulcers (13.2%), 8 with gastric erosions (10.5%), 3 with submucosal tumors (3.9%), 2 with hyperplastic polyps (2.6%), 1 with gastric adenoma (1.3%), and 3 with gastric carcinomas (3.9%). The most frequent endoscopic configuration of gastric involvement with ATLL was the diffuse type with ulceration, and the most common histology was large cell type. Among those with the acute type ATLL, the survival period of those patients with gastric involvement was less than that of the patients without gastric involvement. In contrast, the survival period for lymphoma type ATLL did not differ among the groups regardless of gastric involvement. CONCLUSIONS: This study demonstrated that 30.3% of patients with ATLL had gastric involvement and 13.2% had peptic ulcers. Gastric involvement of ATLL was one of the prognostic factors in acute type ATLL, whereas it had no influence on the prognosis of lymphoma type ATLL.
Keywords: Female Gastroscopy Human Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/ *COMPLICATIONS/MORTALITY Male Middle Age Peptic Ulcer/COMPLICATIONS/DIAGNOSIS Prognosis Stomach Diseases/*COMPLICATIONS/DIAGNOSIS Stomach Neoplasms/*COMPLICATIONS/DIAGNOSIS Survival Rate JOURNAL ARTICLEKWDfemalegastroscopyhumanleukemia-lymphoma,t-cell,acute,htlv-i-associated/KWDcomplications/mortalitymalemiddleagepepticulcer/complications/diagnosisprognosisstomachdiseases/KWDcomplications/diagnosisstomachneoplasms/KWDcomplications/diagnosissurvivalratejournalarticle
961130
M96B1849

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .